Abstract: A connector assembly for protecting electrical connections in a hazardous environment is provided. The connector assembly includes a first connector, a plug casting, and an elongated mesh grip. The plug casting circumscribes and is secured onto the first connector. The elongated mesh grip is coupled to the plug casting, the mesh grip including a mesh sized to surround the electrical cable, the mesh including a first end and a second end. The mesh has a diameter that is a transverse diameter of a channel defined by the mesh and configured to receive an electrical cable therethrough, wherein the diameter of the mesh decreases when one of the first and second ends of the mesh is pulled away from the other of the first and second ends of the mesh.

Abstract: Apparatus and associated methods relate to a 3rd Party Asset Verification module (3PAV module) embodied in a computer system configured to: (1) transmit a unique access code to at least one entity, the unique access code (1a) associated with a user and the user's asset information, and (1b) permits access to the user's asset information stored in the controlled access data store, and (2) in response to a request for data from a broadcasted receiver of the unique access code, the request including the unique access code, returning the user's asset information stored in the controlled access data store. In an illustrative example, the unique code may be generated upon the user providing authorization, over a network, for other parties to access the user's asset information. Various implementations may provide for secure and controlled access to the user's trusted asset data, which may increase efficiency in a consumer-dealer-lender transaction.

Abstract: Apparatus and associated methods relate to a 3rd Party Asset Verification module (3PAV module) embodied in a computer system configured to: (1) transmit a unique access code to at least one entity, the unique access code (1a) associated with a user and the user's asset information, and (1b) permits access to the user's asset information stored in the controlled access data store, and (2) in response to a request for data from a broadcasted receiver of the unique access code, the request including the unique access code, returning the user's asset information stored in the controlled access data store. In an illustrative example, the unique code may be generated upon the user providing authorization, over a network, for other parties to access the user's asset information. Various implementations may provide for secure and controlled access to the user's trusted asset data, which may increase efficiency in a consumer-dealer-lender transaction.

Abstract: A connector assembly for protecting electrical connections in a hazardous environment is provided. The connector assembly includes a first connector, a plug casting, and an elongated mesh grip. The plug casting circumscribes and is secured onto the first connector. The elongated mesh grip is coupled to the plug casting, the mesh grip including a mesh sized to surround the electrical cable, the mesh including a first end and a second end. The mesh has a diameter that is a transverse diameter of a channel defined by the mesh and configured to receive an electrical cable therethrough, wherein the diameter of the mesh decreases when one of the first and second ends of the mesh is pulled away from the other of the first and second ends of the mesh.

Abstract: A transaction authorisation system comprises a user interface unit 30 capable of accepting a transaction authorisation and a utility meter 10 provided at a location having an associated location identifier unique to the location, wherein the utility meter 10 is arranged to communicate with the user interface unit 10, to obtain a transaction authorisation, and to transmit an authorisation request based on the transaction authorisation and location identifier to obtain authorisation of the transaction.

Abstract: A data communication authentication system (10) and method are described. One or more locator nodes (20) are installable at a location (30), the or each locator node (20) including an identifier (21) and a communication system (22) and being arranged to provide said identifier via said communication system (22). The communication authentication system (10) is arranged to generate an authentication code for the location (30) in dependence on identifiers (21) from the one or more locator nodes at the location and is arranged to provide said authentication code on demand for inclusion in a data communication originating locally to said location (30).

Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

Abstract: A transaction authorization system comprises a user interface unit 30 capable of accepting a transaction authorization and a utility meter 10 provided at a location having an associated location identifier unique to the location, wherein the utility meter 10 is arranged to communicate with the user interface unit 10, to obtain a transaction authorization, and to transmit an authorization request based on the transaction authorization and location identifier to obtain authorization of the transaction.

Abstract: An electronic payment unit including includes a data communications interface, a payment card reader and a memory. During a registration process between the electronic payment unit and a registering system at a location having a unique identifier associated with the location, the electronic payment unit is operative to store the unique identifier, or data derived from or including the unique identifier in the memory. The payment card reader is arranged to read a payment card during an electronic transaction, and to form for transmission, via the data communications interface, an electronic payment request including data on the payment card and on the content of the memory. An associated system and method are also disclosed.

Abstract: A data communication authentication system (10) and method are described. One or more locator nodes (20) are installable at a location (30), the or each locator node (20) including an identifier (21) and a communication system (22) and being arranged to provide said identifier via said communication system (22). The communication authentication system (10) is arranged to generate an authentication code for the location (30) in dependence on identifiers (21) from the one or more locator nodes at the location and is arranged to provide said authentication code on demand for inclusion in a data communication originating locally to said location (30).

Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.

Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

Abstract: The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or un branched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.

Abstract: The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or un branched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.

Abstract: The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.

Abstract: A transaction authorisation system comprises a user interface unit 30 capable of accepting a transaction authorisation and a utility meter 10 provided at a location having an associated location identifier unique to the location, wherein the utility meter 10 is arranged to communicate with the user interface unit 10, to obtain a transaction authorisation, and to transmit an authorisation request based on the transaction authorisation and location identifier to obtain authorisation of the transaction.

Abstract: A prodrug of the formula (I): ##STR1## where R.sup.1 is a group such that the compound R.sup.1 NH.sub.2 represents actinomycin D, doxorubicin, mitomycin C, or a nitrogen mustard of the formula (IV): ##STR2## a prodrug of the formula (II): ##STR3## where R.sup.2 is a group such that the compound R.sup.2 OH is a phenolic nitrogen mustard; and processes whereby the prodrugs shown above are made in which a prodrug precursor compound is reacted with 4-nitrobenzyl chloroformate under anhydrous conditions.

Abstract: The present invention provides compounds of the formula (I) wherein each R.sup.1, which may be the same or different, is hydrogen, C.sub.1-4 alkyl, or an electron withdrawing group selected from the group consisting of CF.sub.3 CH.sub.2 or CH.sub.2 C.tbd.CH, R.sup.2 is hydrogen, C.sub.1-4 alkyl, or an electron withdrawing group selected from the group consisting of CF.sub.3 CH.sub.2 or CH.sub.2 C.tbd.CH. The compounds are analogs of trimelamol which have comparable activity but enhanced stability, and are useful as anticancer agents, particularly against ovarian cancer.

Abstract: A prodrug of the formula (I): ##STR1## where R.sup.1 is a group such that the compound R--NH.sub.2 represents actinomycin D, doxorubicin, mitomycin C, or a nitrogen mustard of the formula (IV): ##STR2## a prodrug of the formula (II): ##STR3## where R.sup.1 is a group such that the compound R.sup.2 OH is a phenolic nitrogen mustard; and processes whereby the prodrugs shown above are made in which a prodrug precursor compound is reacted with 4-nitrobenzyl chloroformate under anhydrous conditions.